Clinical Trial Update: Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety, tolerability, and efficacy of a 28-day inhaled CHF 6001 dry powder inhaler in patients with chronic obstructive pulmonary…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• CHF 6001

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: COPD | Phase 2 | Status: COMPLETED